Current status of liquid biopsies for the detection and management of prostate cancer.
biomarker
circulating tumor DNA
circulating tumor cell
prostate cancer
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
01
2019
accepted:
18
04
2019
entrez:
27
6
2019
pubmed:
27
6
2019
medline:
27
6
2019
Statut:
epublish
Résumé
In recent years, new therapeutic options have become available for prostate cancer (PC) patients, generating an urgent need for better biomarkers to guide the choice of therapy and monitor treatment response. Liquid biopsies, including circulating tumor cells (CTCs), circulating nucleic acids, and exosomes, have been developed as minimally invasive assays allowing oncologists to monitor PC patients with real-time cellular or molecular information. While CTC counts remain the most extensively validated prognostic biomarker to monitor treatment response, recent advances demonstrate that CTC morphology and androgen receptor characterization can provide additional information to guide the choice of treatment. Characterization of cell-free DNA (cfDNA) is another rapidly emerging field with novel technologies capable of monitoring the evolution of treatment relevant alterations such as those in DNA damage repair genes for poly (ADP-ribose) polymerase (PARP) inhibition. In addition, several new liquid biopsy fields are emerging, including the characterization of heterogeneity, CTC RNA sequencing, the culture and xenografting of CTCs, and the characterization of extracellular vesicles (EVs) and circulating microRNAs. This review describes the clinical utilization of liquid biopsies in the management of PC patients and emerging liquid biopsy technologies with the potential to advance personalized cancer therapy.
Identifiants
pubmed: 31239778
doi: 10.2147/CMAR.S170380
pii: 170380
pmc: PMC6559244
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5271-5291Déclaration de conflit d'intérêts
Dr. Amir Goldkorn reports personal fees from Acadia Woods (VC firm) outside the submitted work; In addition, Dr. Amir Goldkorn has a patent US8551425B2: Method for cancer detection, diagnosis, and prognosis licensed to Circulogix, Corestone. The authors report no other conflicts of interest in this work.
Références
Am J Pathol. 2000 Jan;156(1):57-63
pubmed: 10623654
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
pubmed: 11240971
Nat Biotechnol. 2002 Apr;20(4):387-92
pubmed: 11923846
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22
pubmed: 12857956
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Cancer Res. 2005 Jun 15;65(12):4993-7
pubmed: 15958538
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Nat Methods. 2006 Jul;3(7):551-9
pubmed: 16791214
Nat Rev Cancer. 2006 Jul;6(7):565-71
pubmed: 16794639
Ann N Y Acad Sci. 2006 Sep;1075:278-81
pubmed: 17108221
Am J Physiol Renal Physiol. 2007 May;292(5):F1657-61
pubmed: 17229675
J Clin Oncol. 2007 May 20;25(15):2035-41
pubmed: 17513807
Clin Cancer Res. 2007 Dec 1;13(23):7053-8
pubmed: 18056182
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Nat Methods. 2008 Oct;5(10):877-9
pubmed: 18806792
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Nature. 2009 Mar 5;458(7234):97-101
pubmed: 19136943
Lancet Oncol. 2009 Mar;10(3):233-9
pubmed: 19213602
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3970-5
pubmed: 19234122
Nat Methods. 2009 May;6(5):377-82
pubmed: 19349980
Clin Cancer Res. 2009 Apr 15;15(8):2630-6
pubmed: 19351754
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cancer Res. 2009 Jul 1;69(13):5601-9
pubmed: 19549916
PLoS One. 2009 Jul 14;4(7):e6229
pubmed: 19597549
Nat Methods. 2010 Feb;7(2):111-8
pubmed: 20111037
Clin Cancer Res. 2010 Jul 1;16(13):3299-318
pubmed: 20501613
Scand J Clin Lab Invest Suppl. 2010;242:46-52
pubmed: 20515277
Cancer Res. 2010 Aug 15;70(16):6420-6
pubmed: 20663903
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65
pubmed: 20823238
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7
pubmed: 20930119
Nat Rev Genet. 2011 Feb;12(2):87-98
pubmed: 21191423
J Cell Biol. 2011 Feb 7;192(3):373-82
pubmed: 21300848
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
Urology. 2011 May;77(5):1265.e9-16
pubmed: 21539977
Nucleic Acids Res. 2011 Sep 1;39(16):7223-33
pubmed: 21609964
Mol Cancer Res. 2011 Aug;9(8):997-1007
pubmed: 21665936
Anal Chem. 2011 Nov 15;83(22):8604-10
pubmed: 22035192
Br J Cancer. 2012 Feb 14;106(4):768-74
pubmed: 22240788
Cell. 2012 Mar 2;148(5):873-85
pubmed: 22385957
Cell. 2012 Mar 2;148(5):886-95
pubmed: 22385958
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Eur Urol. 2013 Feb;63(2):347-53
pubmed: 22502944
PLoS One. 2012;7(4):e35976
pubmed: 22558290
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
Nature. 2012 Jul 26;487(7408):510-3
pubmed: 22763454
Anticancer Res. 2012 Aug;32(8):3507-13
pubmed: 22843938
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
Lancet Oncol. 2012 Nov;13(11):1114-24
pubmed: 23059046
Lancet Oncol. 2012 Nov;13(11):1105-13
pubmed: 23059047
Cancer Discov. 2012 Nov;2(11):995-1003
pubmed: 23093251
PLoS One. 2012;7(11):e49144
pubmed: 23145101
Sci Transl Med. 2012 Nov 28;4(162):162ra154
pubmed: 23197571
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
Nat Rev Clin Oncol. 2013 Apr;10(4):225-34
pubmed: 23459624
Adv Mater. 2013 Jun 4;25(21):2897-902
pubmed: 23529932
Sci Transl Med. 2013 Apr 3;5(179):179ra47
pubmed: 23552373
Genome Med. 2013 Apr 05;5(4):30
pubmed: 23561577
Sci Transl Med. 2013 Apr 10;5(180):180ra48
pubmed: 23576814
Nat Biotechnol. 2013 Jun;31(6):539-44
pubmed: 23609047
BMC Genomics. 2013 May 10;14:319
pubmed: 23663360
Methods. 2013 Dec 1;64(2):144-52
pubmed: 23816790
Eur Urol. 2014 Jun;65(6):1191-7
pubmed: 23954088
Oncogene. 2014 Oct 30;33(44):5173-82
pubmed: 24166498
Oncogene. 2015 Jan 15;34(3):290-302
pubmed: 24441045
PLoS One. 2014 Jan 29;9(1):e86717
pubmed: 24489774
J Clin Oncol. 2014 Apr 10;32(11):1136-42
pubmed: 24616308
Clin Cancer Res. 2014 Mar 15;20(6):1428-44
pubmed: 24634466
Br J Cancer. 2014 May 13;110(10):2462-71
pubmed: 24714754
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
Nat Biotechnol. 2014 May;32(5):479-84
pubmed: 24752078
Nat Med. 2014 Aug;20(8):897-903
pubmed: 24880617
J Clin Oncol. 2014 Nov 1;32(31):3483-9
pubmed: 24888818
Science. 2014 Jul 11;345(6193):216-20
pubmed: 25013076
Prostate. 2014 Oct;74(14):1379-90
pubmed: 25111183
Eur Urol. 2015 Jan;67(1):33-41
pubmed: 25129854
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Int J Cancer. 2015 Apr 15;136(8):1856-62
pubmed: 25219358
Sci Transl Med. 2014 Sep 17;6(254):254ra125
pubmed: 25232177
Clin Genitourin Cancer. 2015 Apr;13(2):130-6
pubmed: 25450039
Cytometry A. 2015 Feb;87(2):137-44
pubmed: 25515318
Oncoscience. 2013 Dec 31;1(1):49-56
pubmed: 25593983
Clin Cancer Res. 2015 May 15;21(10):2315-24
pubmed: 25712683
J Clin Oncol. 2015 Apr 20;33(12):1348-55
pubmed: 25800753
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Cold Spring Harb Protoc. 2015 Apr 01;2015(4):319-23
pubmed: 25834266
J Clin Oncol. 2015 May 10;33(14):1601-8
pubmed: 25847934
Clin Genitourin Cancer. 2015 Oct;13(5):e341-5
pubmed: 25956468
Cancer. 2015 Sep 15;121(18):3240-51
pubmed: 25975562
Urol Oncol. 2015 Sep;33(9):385.e15-20
pubmed: 26027763
Cancer Discov. 2015 Jul;5(7):704-12
pubmed: 26091828
Ann Oncol. 2015 Sep;26(9):1859-65
pubmed: 26117829
Eur Urol. 2015 Dec;68(6):939-45
pubmed: 26188394
J Clin Med. 2015 Jul 07;4(7):1369-79
pubmed: 26239681
Science. 2015 Sep 18;349(6254):1351-6
pubmed: 26383955
PLoS One. 2015 Sep 23;10(9):e0138032
pubmed: 26397728
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Sci Transl Med. 2015 Nov 4;7(312):312re10
pubmed: 26537258
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Oncotarget. 2015 Dec 29;6(42):44781-93
pubmed: 26575023
Sci Rep. 2015 Dec 03;5:17533
pubmed: 26631983
Clin Cancer Res. 2016 Mar 15;22(6):1510-9
pubmed: 26671992
Onco Targets Ther. 2015 Dec 31;9:139-48
pubmed: 26770063
Urol Oncol. 2016 May;34(5):235.e11-6
pubmed: 26795608
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Cancer Discov. 2016 Jun;6(6):584-93
pubmed: 27029895
JAMA Oncol. 2016 Jul 1;2(7):882-9
pubmed: 27032035
Sci Rep. 2016 Apr 22;6:24922
pubmed: 27102850
PLoS One. 2016 May 04;11(5):e0154507
pubmed: 27144529
JAMA Oncol. 2016 Nov 1;2(11):1441-1449
pubmed: 27262168
Anticancer Res. 2016 Jun;36(6):2975-81
pubmed: 27272813
Stat Med. 1989 Apr;8(4):431-40
pubmed: 2727467
Nat Commun. 2016 Jun 22;7:12008
pubmed: 27328849
Clin Cancer Res. 2016 Jul 11;23(3):746-756
pubmed: 27401243
PLoS Genet. 2016 Jul 18;12(7):e1006162
pubmed: 27428049
J Urol. 2017 Jan;197(1):135-142
pubmed: 27436429
Tumour Biol. 2016 Oct;37(10):13687-13694
pubmed: 27473086
BJU Int. 2017 Nov;120(5B):E30-E44
pubmed: 27539393
Oncotarget. 2016 Oct 4;7(40):65364-65373
pubmed: 27588476
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10655-60
pubmed: 27601638
Eur Urol. 2017 Apr;71(4):680-687
pubmed: 27733296
Expert Rev Mol Diagn. 2016 Dec;16(12):1291-1305
pubmed: 27797592
JAMA Oncol. 2017 Jul 1;3(7):996-998
pubmed: 27978570
Med Oncol. 2017 Jan;34(1):12
pubmed: 28012133
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
Curr Opin Genet Dev. 2017 Feb;42:14-21
pubmed: 28126649
Ann Transl Med. 2016 Dec;4(24):480
pubmed: 28149842
Cancer Res. 2017 May 1;77(9):2306-2317
pubmed: 28202510
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):251-258
pubmed: 28374743
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066
Cancer Discov. 2017 Sep;7(9):1006-1017
pubmed: 28450425
Cancer Discov. 2017 Sep;7(9):999-1005
pubmed: 28450426
Ann Oncol. 2017 Jul 1;28(7):1508-1516
pubmed: 28472366
J Mol Diagn. 2017 Sep;19(5):722-732
pubmed: 28723342
Sci Transl Med. 2017 Aug 16;9(403):null
pubmed: 28814544
Prostate. 2017 Oct;77(14):1416-1423
pubmed: 28856701
J Circ Biomark. 2015 May 5;4:3
pubmed: 28936239
Prostate. 2018 Feb;78(2):121-127
pubmed: 29105802
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
BMC Cancer. 2017 Nov 09;17(1):730
pubmed: 29121858
JCO Precis Oncol. 2017;2017:null
pubmed: 29170762
JAMA Oncol. 2018 Jun 1;4(6):868-870
pubmed: 29242909
J Clin Oncol. 2018 Feb 20;36(6):572-580
pubmed: 29272162
Prostate. 2018 Mar;78(4):300-307
pubmed: 29285777
Cancer Discov. 2018 Mar;8(3):288-303
pubmed: 29301747
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253
pubmed: 29504834
PLoS One. 2018 Mar 16;13(3):e0194630
pubmed: 29547634
Cell Physiol Biochem. 2018;46(2):532-545
pubmed: 29614511
Clin Cancer Res. 2018 Aug 1;24(15):3539-3549
pubmed: 29691297
Sci Rep. 2018 Apr 27;8(1):6653
pubmed: 29703916
JAMA Oncol. 2018 Sep 1;4(9):1179-1186
pubmed: 29955787
J Extracell Vesicles. 2018 Aug 07;7(1):1505403
pubmed: 30108686
Nat Commun. 2018 Aug 16;9(1):3279
pubmed: 30115931
Nat Rev Clin Oncol. 2018 Nov;15(11):663-675
pubmed: 30135575
Eur Urol. 2018 Dec;74(6):731-738
pubmed: 30237023
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
J Urol. 1974 Jan;111(1):58-64
pubmed: 4813554
J Urol. 1994 Nov;152(5 Pt 2):1709-13
pubmed: 7933231
Eur J Cancer. 1997 Apr;33(5):787-91
pubmed: 9282118
Cancer Res. 1998 Jan 1;58(1):23-8
pubmed: 9426051
J Natl Cancer Inst. 1998 Feb 4;90(3):233-7
pubmed: 9462681